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osting by EAbstract The present study was taken up to illustrate the mechanism of anti-rheumatic activity of
‘Rheumavedic capsule’, a polyherbal formulation of Vedic-bio Labs, Bangalore, in adjuvant
induced arthritic rats. Anti-inﬂammatory mechanism is illustrated using phlogistic agents induced
paw edema in rats. Analgesic mechanism is illustrated using Eddy’s hot plate and acetic acid
(0.6%v/v) induced writhing in mice. Histopathology of knee joint was studied.
Rheumavedic showed inhibition of inﬂammation mediated through Histamine, 5-Hydroxy trypt-
amine, and Bradykinin. Rheumavedic showed protection in both acetic acid and Eddy’s hot plate
induced pain. Histopathology of knee joint of rat pre-treated with rheumavedic showed signiﬁcant
reduction in the mononuclear inﬁltration, pannus formation and adhesion molecules.
The anti-rheumatic mechanism of rheumavedic is due to; inhibition of inﬂammatory mediators
i.e., Histamine, 5-Hydroxy tryptamine and Bradykinin., protection against prostaglandins mediated
pain, by inhibiting cyclo-oxygenase synthesis and reduction in pannus formation, by inhibiting
mononuclear inﬁltration.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.080 26711651; fax: +91 080
.com (S. Meera).
y. Production and hosting by
Saud University.
lsevier1. Introduction
Rheumatoid arthritis (RA) is a chronic systemic autoimmune
disorder with pain, inﬂammation and restriction of movements
of the limbs due to tissue damage (Gomes et al., 2010). It is
characterised by persistent synovitis, systemic inﬂammation,
and autoantibodies. Fifty percentage of the risk for develop-
ment of rheumatoid arthritis is attributable to genetic factors.
Smoking is the main environmental risk. The disorder is most
typical in women and elderly people. Uncontrolled active
rheumatoid arthritis causes joint damage, disability, decreased
quality of life, and cardiovascular and other comorbidities
(David et al., 2010). Analgesic and anti-inﬂammatory drugs
280 S. Meera et al.e.g., Diclofenac sodium, including steroids e.g., Glucocorti-
coids, are used to suppress the symptoms, while disease-
modifying antirheumatic drugs (DMARDs) e.g., Methotrexate
are required to inhibit or halt the underlying immune process
and prevent long-term damage (Vikas and Stephen, 2007).
Alternative medicines like Ayurveda, Unani, Traditional
Chinese medicine, etc. are more and more used for treatment
of diseases, illness prevention and maintenance of health.
Ayurveda is an ancient, Indian medical science which uses
medicinal plants and herbs for treatment of various diseases.
‘‘Rheumavedic’’ capsule, a polyherbal formulation of
Vedic-bio Labs, Bangalore, contains the extracts of 15 differ-
ent medicinal plants viz., Alpinia galangal, Boswellia serrate,
Asphlatum commiphora mukul, Sida cordifolia, Vitex negun-
do, Withania somnifera, Zingiber ofﬁcinale, Mesua ferrea, Ric-
inus communis, Cedrus deodara, Boerhavia diffusa, Tribulus
terrestris, Aconitum heterophyllum, Calotropis procera. Earlier
studies have proved the anti-rheumatic activity of Rheumav-
edic (Shubhapriya, 2010; Jimtrade, 2010). The constituents of
rheumavedic capsule are used in folk medicine for the
treatment of inﬂammation and pain, associated with arthritis.
Hence, the present study is taken up to illustrate the
mechanism of anti-arthritic activity of ‘‘Rheumavedic
capsule’’.
2. Materials and methods
2.1. Animals
Healthy male rats (Albino Wistar, Sprague–Dawley) weighing
150–200 gm and mice (swiss albino) weighing 25–30 gm,
procured from INVIVO BIOSCIENCES, Bangalore, were
used in the study. Animals were housed for one week prior
to starting the experiment, so as to acclimatize to laboratory
conditions. They were given standard rat feed (Mysore feeds
Pvt. Ltd., Bangalore) and provided with water ad libitum.
The Institutional Animal Ethics Committee approved the
experimental protocols (Reg. No. 152/1999/CPCSEA, renewal
on 12-10-2007). Care of animals was taken according to
CPCSEA guidelines.
2.2. Drugs and chemicals
Rheumavedic was obtained from Vedic Bio-Labs Pvt. Ltd.,
Bangalore. Indomethacin from Sigma–Aldrich, Glycerin I.P.
from Multilabs Pvt. Ltd., Bangalore, acetic acid from
Spectrum reagents and chemicals Pvt. Ltd., Mumbai. Com-
plete Freund’s adjuvant, Lamda-Carrageenan, Bradykinin,
Histamine, and 5-Hydroxy tryptamine were obtained from
Sigma–Aldrich, Diclofenac from Novartis India Ltd., Ahme-
dabad and Tramadol was obtained from Zydus Healthcare
S.A. (Pvt.) Ltd., Ahmedabad. Kits for estimation of ALT,
AST, and total protein were procured from Span Diagnostics
Ltd., Surat, India.
2.3. Anti arthritic activity-adjuvant induced arthritis in rats
Female Sprague–Dawley rats weighing 150–200 g were divided
into four groups of six animals each. Control animals were
administered the vehicle, Group 2 (Arthritic control) animals
were injected with CFA 0.1 mL to sub planter region of righthind paw, For Group 3 and Group 4 animals respectively,
Rheumavedic capsule (54 mg kg1 p.o.) and indomethacin
(10 mg kg1 p.o.) were administered twice a day, from the
day of injection of CFA (0.1 mL in sub planter region) and
continued up to 14th post CFA challenge day. Paw volume
was measured using mercury plethysmograph on 0, 4, 7, 14,
21 day from the day of CFA injection. At the end of the
21st day, blood was withdrawn from retro orbital plexus,
WBC count was found and serum was separated by centrifu-
gation (Remi) at 3000 rpm for 15 min (Meera et al., 2008).
Estimation of ALT, AST (Schumann et al., 2002) and total
protein (Young, 1997) were done using standard RMS kits
and auto analyser.
Histopathological assessment of knee joint was done on
21st day after euthanasia.2.4. Anti-inﬂammatory activity–phlogistic agents induced paw
edema in rats
Male Albino Wistar rats weighing between 150 and 200 g were
divided into ﬁve groups of six rats each. Group 2–5 was further
divided into three sub-groups each.
Animals of Group 1 receive vehicle (distilled water
10 ml kg1 p.o.), animals of Group 2(a), 3(a), 4(a), 5(a) were
subjected to inﬂammation by injecting phlogestic agents prior
to administration of vehicle. Animals of Group 2(b), 3(b),
4(b), 5(b) were administered with rheumavedic (54 mg kg1,
p.o.) followed by 5-HT[0.1 ml (1 mg ml1)], Bradykinin
[0.1 ml (20 lg mll)] 60 min thereafter and Group 4(a), 5(a)
injected Carageenan [0.1 ml (1%)], Histamine [0.1 ml
(1 mg ml1)] 30 min thereafter. Animals of Group 2(c), 3(c),
4(c), 5(c) were administered with indomethacin (10 mg kg1,
i.p.) followed by respective phlogestic agents.
The paw volumes were measured immediately (0 h) and then
at predetermined intervals; for Carageenan at (30 min, 1 h, 2 h,
3 h, 4 h, 5 h, and 6 h), for Bradykinin at (10 min, 20 min,
30 min, 60 min, and 120 min), for Histamine and 5-HT at
(30 min, 60 min, 90 min, 120 min, 150 min, and 180 min) using
plethysmometer (Yunnus, 2005). Percent change in paw
volume was calculated using the following formula.
%Inhibition ¼ 100 ðControl mean=Treated mean 100Þ2.5. Analgesic activity
2.5.1. Acetic acid induced writhing test in mice
The animals (Swiss–albino mice) were divided into three groups
of six each. The ﬁrst group of animals was treated as control
and received 0.6% v/v acetic acid (10 ml kg1, i.p.), second
group of animals received the standard drug diclofenac sodium
(20 mg kg1, p.o.), and third group of animals was adminis-
tered rheumavedic (54 mg kg1, p.o.). After 30 min of the
administration of rheumavedic and diclofenac sodium, all the
groups of mice were injected with aqueous acetic acid. The
numbers of writhing episode were counted for 10 min (Schu-
mann et al., 2002) 20–05 and the number of wriths produced
in rheumavedic treated mice was compared with control mice.
%inhibition of abdominal constrictions
¼ ðControl mean Treated meanÞ  100
Control mean
Figure 1 Effect of rheumavedic on Paw edema. Values are expressed as mean ± SEM. n= 6; one way ANOVA followed by Tukey’s
multiple comparison test, +++P< 0.001 vs control, **P< 0.01 vs arthritic control ***P< 0.001 vs arthritic control.
Figure 2 Effect of rheumavedic on AST, ALT, and TP in CFA
treated rats. Values are expressed as mean ± SEM. n= 6; one
way ANOVA followed by Tukey’s multiple comparison test,
+P< 0.05 vs control, *P< 0.05 vs arthritic control ***P< 0.001
vs arthritic control.
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The animals (Swiss–albino mice) were divided into three
groups of six each. The ﬁrst group was treated as control
and pain was induced by placing on hotplate, second group
received the standard drug tramadol (25 mg kg1, p.o.) and
third group was administered with rheumavedic (54 mg kg1,
p.o.). The time for licking paws or jumping in hot plate (main-
tained at 55 ± 0.5 C) was recorded as response, prior and 20,
60, 120, and 150 min after administration of rheumavedic/
tramadol. A cut off time of 15 s was set to avoid tissue damage
(Meera et al., 2008).2.6. Histopathology
After euthanasia on day 21, the hind paws amputated above
the knee joint were ﬁxed in 7.4% formalin solution. The paws
were then decalciﬁed using 10% Nitric acid, embedded in
parafﬁn and sectioned in a mid-sagittal plane. The sections
of articulation of the tarsal joints were stained with heamtoxy-
lin and eosin and were examined microscopically for mononu-
clear inﬁltration, pannus formation and bone destruction
(Meera et al., 2008).
2.7. Statistical analysis
The results were expressed as Mean ± SEM and analysis was
carried out by one-way ANOVA, Post-hock analysis was done
by Tukey’s multiple comparison tests to estimate the signiﬁ-
cance of difference between various individual groups.
P< 0.05 was considered as signiﬁcant.3. Results
3.1. Adjuvant induced arthritis in rats
3.1.1. Paw volume
Rheumavedic decreased the paw volume on day 4, 7, 14, and
21 respectively (Fig. 1).
3.1.2. Haematological parameter
In arthritis control rats WBC count was (13.9 ± 0.75)
· 103cells/mm3. The rheumavedic and indomethacin treat-
ments reduced the WBC count to (8.85 ± 0.59) · 103cells/
mm3 and (7.15 ± 0.65) · 103cells/mm3, respectively.
ab
c
Figure 3 TS of knee joint of (a) normal control rat, showing no
mononuclear inﬁltration and pannus formation [H&E, 100·], (b)
arthritic rat showing mononuclear inﬁltration, bone erosion
[H&E, 400·] and (c) rheumavedic treated rat showing reduced
mononuclear inﬁltration and bone erosion [H&E, 100·].
Figure 4 Analgesic effect of Rheumavedic using Eddy’s hot-
plate. Values are expressed as mean ± S.E.M. n= 6; one way
ANOVA followed by Tukey’s multiple comparison test. Signiﬁ-
cance at *P< 0.05, **0.01 and ***0.001 vs vehicle control.
282 S. Meera et al.3.1.3. Lysozomal enzymes
Rheumavedic signiﬁcantly decreased the lysozomal enzyme
ALT, AST and total protein compared with arthritic rats, as
shown in the Fig. 2.
3.1.4. Histopathological studies of CFA induced arthritis in rats
Section of the synovial joint of a normal control rat shows in-
tact articular hyaline cartilage (Fig. 3a), subchondrial bone
layer and adjacent synovial layer. The synovial layer shows
synovial lining cells within normal range. The synovial subep-
ithelium shows ﬁbrocollagenous stroma with vascular spaces
(Fig. 3a). Section of the synovial joint of CFA treated rat
shows partially distorted articular hyaline cartilage with intact
subchondrial bone layer and partially effaced synovial layer.
The distorted articular cartilage i.e., bone erosion is replaced
by mixed inﬂammatory cells comprising predominantlyneutrophils and some lymphocytes. The synovial subepitheli-
um shows ﬁbrocollagenous stroma with vascular spaces
(Fig. 3b). Section of the synovial joint of rheumavedic treated
shows intact articular hyaline cartilage (Fig. 3c), subchondrial
bone layer and adjacent synovial layer. The synovial layer
shows synovial lining cells within normal range. The synovial
subepithelium shows ﬁbrocollagenous stroma with vascular
spaces (Fig. 3c).
3.2. Phlogistic agents induced paw edema in rats
Rheumavedic signiﬁcantly reduced the Carrageenan,
Histamine, 5-HT, Bradykinin induced paw edema respectively
(Table. 1).
3.3. Analgesic activity
3.3.1. Acetic acid induced writhing test in mice
Rheumavedic when compared to control animals, signiﬁcantly
(P< 0.01) decreased the number of acetic acid induced-
writhing episodes and the percentage protection was 41.2%,
while the reference drug, diclofenac sodium showed 66.4%
protection.
3.3.2. Eddy’s hotplate
Fig. 4 shows the time interval of the anti-nociception produced
by Rheumavedic. The effect reached a peak signiﬁcantly at
120 min after administration and then gradually decreased.
4. Discussion and conclusion
In the present study an attempt is made to illustrate mecha-
nism of the action of Rheumavedic whose, anti-rheumatoid
arthritis activity has been proved (Shubhapriya, 2010). Inﬂam-
mation, pain and pannus formation are the integral parts of
arthritis. Hence, we tried to elucidate the mechanism of action
of rheumavedic by studying its effect on these three
components.
Table 1 Effect of rheumavedic on phlogestic agents induced paw edema in rat.
Group Paw volume (ml) at diﬀerent time intervals
0 min 10 min 20 min 30 min 60 min 90 min 120 min 150 min 180 min 240 min 360 min
Histamine (1mg ml1) 0.922 ± 0.037 1.257 ± 0.066 1.267 ± 0.033 1.237 ± 0.041 1.097 ± 0.016 1.070 ± 0.018 1.038 ± 0.043
Rheumavedic
(54 mg kg1, p.o.)
+ Histamine
0.875 ± 0.103 1.188 ± 0.026 1.148 ± 0.027 1.088 ± 0.038* 1.043 ± 0.028 1.023 ± 0.040 1.010 ± 0.033
Indomethacin
(10 mg kg1, i.p.)
+ Histamine
0.937 ± 0.025 1.138 ± 0.061 1.085 ± 0.051* 1.055 ± 0.039** 1.057 ± 0.039 1.093 ± 0.030 1.027 ± 0.045
5-HT (1 mg ml1) 0.930 ± 0.021 1.342 ± 0.021 1.278 ± 0.017 1.245 ± 0.017 1.155 ± 0.021 1.100 ± 0.017 1.029 ± 0.029
Rheumavedic
(54 mg kg1, p.o.)
+ 5-HT
0.920 ± 0.020 1.243 ± 0.011* 1.220 ± 0.020 1.177 ± 0.030 1.118 ± 0.028 1.037 ± 0.040 1.010 ± 0.033
Indomethacin
(10 mg kg1, i.p.)
+5-HT
0.938 ± 0.019 1.110 ± 0.029*** 1.160 ± 0.026** 1.140 ± 0.045* 1.127 ± 0.015 1.072 ± 0.027 0.998 ± 0.007
Carrageenan (1%) 0.933 ± 0.025 1.057 ± 0.035 1.187 ± 0.018 1.390 ± 0.025 1.365 ± 0.041 1.318±0.031
Rheumavedic
(54 mg kg1, p.o.)
+ Carrageenan
0.957 ± 0.957 1.037 ± 1.037 1.205 ± 1.205 1.248 ± 1.248* 1.308 ± 1.308 1.244 ± 1.244
Indomethacin
(10 mg kg-1, i.p.)
+ Carrageenan
0.972 ± 0.031 1.038 ± 0.034 1.130 ± 0.041 1.132 ± 0.041*** 1.173 ± 0.044** 1.178 ± 0.041*
Bradykinin
(20 lg mll)
0.927 ± 0.036 1.313 ± 0.028 1.320 ± 0.021 1.233 ± 0.026 1.223 ± 0.027 1.150 ± 0.026
Rheumavedic
(54 mg kg1, p.o.)
+ Bradykinin
0.958 ± 0.028 1.150 ± 0.029*** 1.108 ± 0.029*** 1.038 ± 0.026*** 1.065 ± 0.018 1.112 ± 0.022
Indomethacin
(10 mg kg1, i.p.)
+ Bradykinin
0.963 ± 0.036 1.145 ± 0.030*** 1.175 ± 0.032** 1.153 ± 0.038 1.178 ± 0.036 1.148 ± 0.013



























284 S. Meera et al.Inﬂammation, an integral part of arthritis, causes various
abnormalities like swelling, redness, loss of function through
numerous mediators like Cytokines, Bradykinin, Histamine,
Eicosanoids, and Platelet activating factor (Soneera and Vijay,
2005). So in our study we selected some of the known phlogis-
tic agents like Carrageenan, Histamine, 5-HT and Bradykinin
to understand the anti-inﬂammatory component of rheumave-
dic. We found that Rheumavedic inhibited 10.21% (P< 0.05)
of Carrageenan induced paw volume at 3rd h. 9.34%, 11.99%
(P< 0.05) of Histamine induced paw volume at 60 min and
90 min respectively. 7.32% (P< 0.05) of 5-HT induced paw
volume at 30 min. 12.43%, 16.03%, 15.81% (P< 0.001) of
Bradykinin induced paw volume at 10 min, 20 min, and
30 min respectively. These results show that, though not very
potent, Rheumavedic decreased the inﬂammation by antagon-
ising/inhibiting the inﬂammatory mediators i.e., Histamine, 5-
HT and Bradykinin.
Analgesic activity of rheumavedic was illustrated through,
acetic acid induced, prostaglandin’s mediated pain, where per-
centage protection was found to be 41.2% (P< 0.001). Anal-
gesic activity of rheumavedic using Eddy’s hotplate was found
to be maximum at 120 min. This indicates that rheumavedic
acts as both peripheral (Somsak, 2009) and central analgesic
(Meera et al., 2008).
Pannus formation is one of the major events which leads to
cartilage destruction and bone erosion in rheumatoid arthritis.
The pannus formed due to CFA was reduced by rheumavedic.
It is supported by histological studies of knee joints. Fig. 3a is
TS of knee joint of control rat. Severe neutrophil inﬁltration,
pannus formation and bone erosion is seen in knee joint of ar-
thritic control rat as shown in Fig. 3b. On treatment with rheu-
mavedic there is reduction in the neutrophil inﬁltration,
pannus formation and bone as shown in Fig. 3c, respectively.
Rheumavedic decreased the elevated level of WBC, thus lead-
ing to reduction in mononuclear inﬁltration and hence reduced
pannus formation (Meera et al., 2008; Yunnus, 2005).
In summary, the anti-rheumatic mechanism of rheumavedic
is due to,
i. Inhibition of inﬂammation by inhibiting inﬂammatory
mediators i.e., Histamine, 5-HT, and Bradykinin.
ii. Protection against prostaglandins mediated pain in
mice, by inhibiting cyclo-oxygenase synthesis.
iii. Reduction in pannus formation, by inhibiting mononu-
clear inﬁltration.Conﬂict of interest
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